Abstract: The present invention relates to method of preventing, treating or attenuating obesity-related manifestations in a human or non-human mammal subject in need thereof, said method comprising orally administering to the subject a composition comprising an effective amount Hafnia alvei probiotics; wherein said obesity-related parameters are selected from the group of hyperphagia, increased fat mass on lean mass ratio, increased waist circumference, postprandial hyperglycemia, fasting hyperglycemia and hypercholesterolemia.

Abstract: The present invention relates to ClpB expressing bacteria and their impact on obesity. The present invention relates to bacterial ClpB protein and ClpB expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one ClpB expressing bacterium as well as probiotics not expressing ClpB protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.

Abstract: The present invention relates to CIpB expressing bacteria and their impact on obesity. The present invention relates to bacterial CIpB protein and CIpB expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one CIpB expressing bacterium as well as probiotics not expressing CIpB protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.

Abstract: The present invention relates to bacterial Clp B protein and Clp B expressing bacteria and their impact on diseases or disorders related to reduced appetite, increased appetite and/or anxiety. The invention further relates to compositions related to bacterial ClpB protein and to its use in the immunization against a disorder related to reduced appetite and/or anxiety.

Abstract: The present invention relates to bacterial Clp B protein and Clp B expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one Clp B expressing bacterium as well as probiotics not expressing Clp B protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.

Abstract: A method to grant a supplicant access to a data communication network and related devices is claimed. The supplicant is associated to a Medium Access Control address and is coupled to a port of an authenticator of the data communication network. The method comprises: a step of transmitting an authentication request by the authenticator to an authentication server being coupled thereto; and a step of making by the authentication server an authentication decision based upon predefined rules and conditions; and a step of transmitting by the authentication server to the authenticator an authentication reply that comprises a result of the authentication decision.